Comments
Loading...

Coherus BioSciences Analyst Ratings

CHRSNASDAQ
Logo brought to you by Benzinga Data
$0.7818
-0.03-4.27%
At close: -
$0.7712
-0.01-1.36%
After Hours: Apr 4, 6:06 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$21.00
Lowest Price Target1
$1.50
Consensus Price Target1
$9.06

Coherus BioSciences Analyst Ratings and Price Targets | NASDAQ:CHRS | Benzinga

Coherus BioSciences Inc has a consensus price target of $9.06 based on the ratings of 9 analysts. The high is $21 issued by Mizuho on November 16, 2022. The low is $1.5 issued by UBS on August 16, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Baird on March 11, 2025, January 23, 2025, and December 5, 2024, respectively. With an average price target of $6.67 between HC Wainwright & Co., HC Wainwright & Co., and Baird, there's an implied 764.45% upside for Coherus BioSciences Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Nov 24
2
Dec 24
1
Jan
1
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Baird
UBS
Truist Securities
Barclays

1calculated from analyst ratings

Analyst Ratings for Coherus BioSciences

Buy NowGet Alert
03/11/2025Buy Now807.68%HC Wainwright & Co.
Douglas Tsao51%
$7 → $7ReiteratesBuy → BuyGet Alert
01/23/2025Buy Now807.68%HC Wainwright & Co.
Douglas Tsao51%
$7 → $7ReiteratesBuy → BuyGet Alert
12/05/2024Buy Now678.01%Baird
Colleen Kusy34%
$4 → $6MaintainsOutperformGet Alert
12/04/2024Buy Now807.68%HC Wainwright & Co.
Douglas Tsao51%
$7 → $7ReiteratesBuy → BuyGet Alert
11/08/2024Buy Now418.67%Baird
Colleen Kusy34%
$8 → $4MaintainsOutperformGet Alert
11/07/2024Buy Now1456.02%HC Wainwright & Co.
Douglas Tsao51%
$12 → $12ReiteratesBuy → BuyGet Alert
09/16/2024Buy Now1456.02%HC Wainwright & Co.
Douglas Tsao51%
$12 → $12ReiteratesBuy → BuyGet Alert
08/16/2024Buy Now94.5%UBS
Ashwani Verma45%
$4 → $1.5DowngradeBuy → NeutralGet Alert
08/05/2024Buy Now1456.02%HC Wainwright & Co.
Douglas Tsao51%
$12 → $12ReiteratesBuy → BuyGet Alert
07/01/2024Buy Now937.34%Baird
Colleen Kusy34%
$9 → $8MaintainsOutperformGet Alert
05/24/2024Buy Now1456.02%HC Wainwright & Co.
Douglas Tsao51%
$12 → $12ReiteratesBuy → BuyGet Alert
05/13/2024Buy Now807.68%Truist Securities
Robyn Karnauskas55%
$8 → $7MaintainsBuyGet Alert
05/10/2024Buy Now1456.02%HC Wainwright & Co.
Douglas Tsao51%
$11 → $12MaintainsBuyGet Alert
03/20/2024Buy Now1326.35%HC Wainwright & Co.
Douglas Tsao51%
$13 → $11MaintainsBuyGet Alert
03/14/2024Buy Now1585.68%HC Wainwright & Co.
Douglas Tsao51%
$13 → $13ReiteratesBuy → BuyGet Alert
01/23/2024Buy Now1067.01%Baird
Colleen Kusy34%
$11 → $9MaintainsOutperformGet Alert
01/23/2024Buy Now937.34%Truist Securities
Robyn Karnauskas55%
$12 → $8MaintainsBuyGet Alert
12/27/2023Buy Now1585.68%HC Wainwright & Co.
Douglas Tsao51%
$13 → $13ReiteratesBuy → BuyGet Alert
12/07/2023Buy Now1585.68%HC Wainwright & Co.
Douglas Tsao51%
$13 → $13ReiteratesBuy → BuyGet Alert
11/28/2023Buy Now1456.02%Truist Securities
Robyn Karnauskas55%
→ $12ReiteratesBuy → BuyGet Alert
11/17/2023Buy Now1326.35%Baird
Colleen Kusy34%
→ $11Initiates → OutperformGet Alert
11/08/2023Buy NowMaxim Group
Jason McCarthy41%
DowngradeBuy → HoldGet Alert
11/07/2023Buy Now1585.68%HC Wainwright & Co.
Douglas Tsao51%
$20 → $13MaintainsBuyGet Alert
10/23/2023Buy Now807.68%Barclays
Balaji Prasad53%
$8 → $7MaintainsOverweightGet Alert
09/26/2023Buy Now2493.36%Truist Securities
Robyn Karnauskas55%
→ $20ReiteratesBuy → BuyGet Alert
09/26/2023Buy Now2493.36%HC Wainwright & Co.
Douglas Tsao51%
→ $20ReiteratesBuy → BuyGet Alert
08/07/2023Buy Now807.68%UBS
Ashwani Verma45%
$11 → $7MaintainsBuyGet Alert
08/03/2023Buy Now2493.36%HC Wainwright & Co.
Douglas Tsao51%
$24 → $20MaintainsBuyGet Alert
07/24/2023Buy Now1456.02%Citigroup
Robyn Karnauskas55%
→ $12Initiates → BuyGet Alert
07/14/2023Buy Now2493.36%Truist Securities
Robyn Karnauskas55%
$22 → $20MaintainsBuyGet Alert
06/28/2023Buy Now2752.7%Truist Securities
Robyn Karnauskas55%
→ $22ReiteratesBuy → BuyGet Alert
06/20/2023Buy Now2752.7%Truist Securities
Robyn Karnauskas55%
$24 → $22MaintainsBuyGet Alert
06/20/2023Buy Now3012.03%HC Wainwright & Co.
Douglas Tsao51%
→ $24ReiteratesBuy → BuyGet Alert
06/15/2023Buy Now3012.03%Truist Securities
Robyn Karnauskas55%
→ $24ReiteratesBuy → BuyGet Alert
06/06/2023Buy Now3012.03%HC Wainwright & Co.
Douglas Tsao51%
→ $24Reiterates → BuyGet Alert
06/01/2023Buy Now3012.03%HC Wainwright & Co.
Douglas Tsao51%
→ $24ReiteratesBuy → BuyGet Alert
05/23/2023Buy Now937.34%Barclays
Balaji Prasad53%
$13 → $8MaintainsOverweightGet Alert
05/09/2023Buy Now3012.03%HC Wainwright & Co.
Douglas Tsao51%
$26 → $24MaintainsBuyGet Alert
05/01/2023Buy Now3012.03%Truist Securities
Robyn Karnauskas55%
→ $24Initiates → BuyGet Alert
03/28/2023Buy Now1326.35%UBS
Ashwani Verma45%
→ $11UpgradeNeutral → BuyGet Alert
03/08/2023Buy Now1585.68%Barclays
Balaji Prasad53%
$15 → $13MaintainsOverweightGet Alert
03/07/2023Buy Now3271.37%HC Wainwright & Co.
Douglas Tsao51%
$30 → $26MaintainsBuyGet Alert
11/16/2022Buy Now2623.03%Mizuho
Salim Syed43%
$28 → $21MaintainsBuyGet Alert
11/14/2022Buy Now1326.35%JP Morgan
Chris Schott60%
$13 → $11MaintainsNeutralGet Alert
08/16/2022Buy Now3530.71%Mizuho
Salim Syed43%
$25 → $28MaintainsBuyGet Alert
06/14/2022Buy Now807.68%UBS
Ashwani Verma45%
→ $7Initiates → NeutralGet Alert
05/20/2022Buy Now3141.7%Mizuho
Salim Syed43%
$30 → $25MaintainsBuyGet Alert
05/09/2022Buy Now1845.02%Barclays
Balaji Prasad53%
$20 → $15MaintainsOverweightGet Alert

FAQ

Q

What is the target price for Coherus BioSciences (CHRS) stock?

A

The latest price target for Coherus BioSciences (NASDAQ:CHRS) was reported by HC Wainwright & Co. on March 11, 2025. The analyst firm set a price target for $7.00 expecting CHRS to rise to within 12 months (a possible 807.68% upside). 13 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Coherus BioSciences (CHRS)?

A

The latest analyst rating for Coherus BioSciences (NASDAQ:CHRS) was provided by HC Wainwright & Co., and Coherus BioSciences reiterated their buy rating.

Q

When was the last upgrade for Coherus BioSciences (CHRS)?

A

The last upgrade for Coherus BioSciences Inc happened on March 28, 2023 when UBS raised their price target to $11. UBS previously had a neutral for Coherus BioSciences Inc.

Q

When was the last downgrade for Coherus BioSciences (CHRS)?

A

The last downgrade for Coherus BioSciences Inc happened on August 16, 2024 when UBS changed their price target from $4 to $1.5 for Coherus BioSciences Inc.

Q

When is the next analyst rating going to be posted or updated for Coherus BioSciences (CHRS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Coherus BioSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Coherus BioSciences was filed on March 11, 2025 so you should expect the next rating to be made available sometime around March 11, 2026.

Q

Is the Analyst Rating Coherus BioSciences (CHRS) correct?

A

While ratings are subjective and will change, the latest Coherus BioSciences (CHRS) rating was a reiterated with a price target of $7.00 to $7.00. The current price Coherus BioSciences (CHRS) is trading at is $0.77, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch